TG Therapeutics, Inc. TGTX

57.43 (0.09) (0.16%) as of 25 Sep
Market cap
$8.8B
P/E
18.9×
Growth Flags show if company had growth for consecutive years

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
447.18 23.38 12.67 (223.81) (348.10) (279.38) (172.87) (173.48) (118.48) (78.25)
Depreciation & Amortization
(2.33) (4.71) 0.57 2.03 2.09 1.27 0.62 (0.03) 0.14 0.52
Non Cash Items (Other)
(275.09) 50.11 40.01 47.26 62.59 83.36 14.08 16.83 16.00 7.37
Accounts Receivable Change
(176.44) (78.09) (51.09) 1.39 (1.39) (0.01) (0.01) 0.01 (0.02) 0.10
Change in inventories
(33.45) (66.85) (36.94) — — — — — — —
Change in payables and accrued liability
55.88 22.84 0.19 (11.01) 15.99 11.63 (4.79) 10.96 11.02 6.49
Change in other assets and liabilities
(40.52) 12.81 3.18 7.97 (26.82) (31.39) 30.17 16.71 (2.45) 2.28
Operating Cash Flow
(24.77) (40.52) (31.41) (176.17) (295.63) (214.51) (132.81) (128.92) (93.76) (61.59)
Capital expenditures
(0.21) (0.04) — (0.01) (0.40) (0.36) (0.13) (0.09) 0.00 (0.34)
Short Term Investments Change (Net)
15.26 0.38 (50.65) (20.00) 0.07 (24.15) (0.59) 1.27 (8.21) 29.50
Long-Term Investments Change (Net)
(1.25) (1.37) — — — — — (31.23) (28.01) (2.61)
Investing cash flow
13.80 (1.04) (50.65) (20.01) (0.33) (24.51) (0.72) 1.18 (8.21) 26.55
Repayment/Issuance of Debt (Net)
— 137.26 25.00 (0.97) 40.00 (1.99) 29.99 — — —
Equity Repurchase (Common, Net)
(89.73) (7.85) 47.83 0.58 2.44 679.83 175.02 113.64 133.66 5.03
Other financial activities
— (0.89) (0.12) 23.30 (1.02) 84.26 (0.79) 16.71 16.07 (0.01)
Financing cash flow
(89.73) 128.53 72.71 (0.39) 41.42 679.83 204.21 113.64 133.66 5.02
Change in Cash
(100.70) 86.97 (9.36) (196.57) (254.55) 440.81 70.69 (14.11) 31.69 (30.03)
Beginning Cash
181.19 94.22 103.58 300.15 554.70 113.89 43.20 57.31 25.61 55.64
Ending Cash
80.49 181.19 94.22 103.58 300.15 554.70 113.89 43.20 57.31 25.61
Stock Based Compensation
64.67 42.54 37.93 44.66 61.27 80.29 11.34 12.89 15.95 7.51
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(194.54) (109.30) (84.66) (1.65) (12.22) (19.76) 25.37 27.67 8.57 8.78
Investments Change (Net)
14.01 (0.99) (50.65) (20.00) 0.07 (24.15) (0.59) 1.27 (8.21) 26.89
Issuance/Purchase of Shares
(89.73) (7.85) 47.83 0.58 2.44 679.83 175.02 113.64 133.66 5.03
Other line items
Revenue per Employee
1.54 0.97 0.89 0.01 0.02 0.00 0.00 0.00 0.00 0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates